ImmunityBio (IBRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.22
- Estimate
- -$0.08
- Surprise
- -175.0%
- Revenue (period 2026-06-30)
- $51.2M
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue source: xbrl.
How the report landed
ImmunityBio (IBRX) reported a wider loss than forecast — diluted EPS of -$0.22 against the -$0.08 estimate (a 175.0% shortfall). TrendMatrix's engine moved from Sell (6.2/10) to Hold at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IBRX Sell at 6.4/10.
2 of the last 4 quarters beat the estimate; this quarter's -175.0% surprise compares with a -31.8% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Risk below floor (1.7 < 3.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.92
- Price target
- $10.84
- Stop
- $7.36
- Upside to target
- +36.9%
- Reward-to-risk
- 3.5:1
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
IBRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $8.38B
- P/E (fwd)
- -62.4
- 52-week range
- $1.95–$12.43
- Off 52-week high
- 36.3%
- RSI (14)
- 52
- Volume vs avg
- 1.54×
- Score today
- 6.4/10